Gynaecological Care for Transgender People in France in 2024.
GyneTrans
1 other identifier
observational
246
1 country
1
Brief Summary
To date, the transgender population, still poorly characterized, tends to increase. The impact of gender-affirming hormone therapy (GAHT) in this population remains poorly understood, and few data are published on the gynecological repercussions of such therapy. A recent literature review by a French team suggests gynecological follow-up procedures for transgender people.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Jun 2024
Typical duration for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
April 4, 2024
CompletedFirst Posted
Study publicly available on registry
April 10, 2024
CompletedStudy Start
First participant enrolled
June 3, 2024
CompletedPrimary Completion
Last participant's last visit for primary outcome
June 16, 2026
CompletedStudy Completion
Last participant's last visit for all outcomes
June 16, 2026
CompletedJune 30, 2026
June 1, 2026
2 years
April 4, 2024
June 26, 2026
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Percentage of people aware of gynaecological recommendations.
Percentage of transgender people who know regular gynaecological recommendations in France, thanks to a homemade questionnaire
24 months after inclusion day
Secondary Outcomes (4)
Percentage of people aware of cancer risks
24 months after inclusion day
Percentage of people aware of contraception in transgender male population
24 months after inclusion day
Percentage of people aware of fertility and the impact of hormone treatments
24 months after inclusion day
Percentage of people aware of gynaecological repercussions of masculinizing hormone treatment in transgender male population
24 months after inclusion day
Study Arms (1)
Transgender
Transgender population in France, male to female and female to male.
Interventions
A flyer with QR code leading to the online questionnaire will be sent to trans associations and healthcare networks for distribution to the target population.
Eligibility Criteria
Transgender people (male and female) will be approached via Trans associations (face-to-face and online) and the care networks in place at national level. An online link for completing the questionnaire will be sent to trans associations and healthcare networks for distribution to the target population via a paper or digital flyer.
You may qualify if:
- French-speaking transgender person (transgender women or transgender men)
- age ≥18 years
You may not qualify if:
- age \<18 years
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Hopital Haut-Lévêque
Pessac, 33604, France
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
April 4, 2024
First Posted
April 10, 2024
Study Start
June 3, 2024
Primary Completion
June 16, 2026
Study Completion
June 16, 2026
Last Updated
June 30, 2026
Record last verified: 2026-06